Aclaris Therapeutics, Inc.
ACRS· Nasdaq
ACRSAclaris Therapeutics, Inc.
Filed Feb 24, 2022 · 10-K · 55 days after period end · 0001558370-22-001838
derived · Computed from the longer spans the company filed.
| Metric | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019dderived from reported figures | Q4 2018 |
|---|---|---|---|---|
| Revenue | $1.50M | $1.58M | $1.10M | $3.67M |
| Net Income | -$22.80M | -$13.17M | -$18.59M | -$38.55M |
| EPS Diluted | — | — |
Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR
| — |
| -$0.99 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2021 · filed Feb 24, 2022 · 55 d after period end
